814 related articles for article (PubMed ID: 31200846)
21. Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
Sekito S; Terabe T; Shibahara T; Onishi T
Anticancer Res; 2021 Apr; 41(4):2183-2186. PubMed ID: 33813431
[TBL] [Abstract][Full Text] [Related]
22. Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials).
Perez IM; Jambor I; Kauko T; Verho J; Ettala O; Falagario U; Merisaari H; Kiviniemi A; Taimen P; Syvänen KT; Knaapila J; Seppänen M; Rannikko A; Riikonen J; Kallajoki M; Mirtti T; Lamminen T; Saunavaara J; Pahikkala T; Boström PJ; Aronen HJ
J Magn Reson Imaging; 2020 May; 51(5):1556-1567. PubMed ID: 31750988
[TBL] [Abstract][Full Text] [Related]
23. Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population.
Fascelli M; Rais-Bahrami S; Sankineni S; Brown AM; George AK; Ho R; Frye T; Kilchevsky A; Chelluri R; Abboud S; Siddiqui MM; Merino MJ; Wood BJ; Choyke PL; Pinto PA; Turkbey B
Urology; 2016 Feb; 88():125-34. PubMed ID: 26680244
[TBL] [Abstract][Full Text] [Related]
24. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
[TBL] [Abstract][Full Text] [Related]
26. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
[TBL] [Abstract][Full Text] [Related]
27. Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance.
Radtke JP; Boxler S; Kuru TH; Wolf MB; Alt CD; Popeneciu IV; Steinemann S; Huettenbrink C; Bergstraesser-Gasch C; Klein T; Kesch C; Roethke M; Becker N; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):288-96. PubMed ID: 26078202
[TBL] [Abstract][Full Text] [Related]
28. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
Guo S; Zhang J; Wang Y; Jiao J; Li Z; Cui C; Chen J; Yang W; Ma S; Wu P; Jing Y; Wen W; Kang F; Wang J; Qin W
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):288-293. PubMed ID: 38160227
[TBL] [Abstract][Full Text] [Related]
29. Are targeted prostate biopsies ready to replace systematic prostate biopsies?
Celma A; López R; Roche S; Planas J; Regis L; Placer J; Borque A; Esteban LM; de Torres I; Morote J
Actas Urol Esp (Engl Ed); 2019 Dec; 43(10):573-578. PubMed ID: 31679807
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
31. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
Schouten MG; van der Leest M; Pokorny M; Hoogenboom M; Barentsz JO; Thompson LC; Fütterer JJ
Eur Urol; 2017 Jun; 71(6):896-903. PubMed ID: 28063613
[TBL] [Abstract][Full Text] [Related]
32. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
33. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
34. Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study.
Falagario U; Jambor I; Taimen P; Syvänen KT; Kähkönen E; Merisaari H; Montoya Perez I; Knaapila J; Steiner A; Verho J; Tewari A; Aronen HJ; Carrieri G; Boström PJ; Ettala O
World J Urol; 2021 Jun; 39(6):1879-1887. PubMed ID: 32778912
[TBL] [Abstract][Full Text] [Related]
35. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
Kim MJ; Park SY
J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
[TBL] [Abstract][Full Text] [Related]
37. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
[TBL] [Abstract][Full Text] [Related]
38. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
[TBL] [Abstract][Full Text] [Related]
40. IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy.
Merisaari H; Jambor I; Ettala O; Boström PJ; Montoya Perez I; Verho J; Kiviniemi A; Syvänen K; Kähkönen E; Eklund L; Pahikkala T; Vainio P; Saunavaara J; Aronen HJ; Taimen P
J Magn Reson Imaging; 2019 Nov; 50(5):1641-1650. PubMed ID: 30903647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
